CRV ssigns new pre-clinical candidate for auto-immune disorders and cancer to BioSphings AG.

Dr Amtmann’s earlier research at DKFZ had selected the lead compound from a large anti-viral screen and subsequently found that the drug was highly selective for a particular form of sphingomyelinases that were up-regulated in tissue and cells showing pathogenic phenotype but not to the same extent in normal tissues. Neutral Sphingomyelinase is a critical enzyme involved in the Fas/CD95 driven apoptotic pathway, and it is thought that the abundance of the enzyme in these diseased cells prevents the cells from undergoing apoptosis or ‘programmed cell death’ to completion. For example in arthritis, inflammation is caused by a build up of activated T-cells. In a normal immune response the activated T-cells will die naturally once they have completed their task. Dr Amtmann has shown that an inhibitor of neutral sphingomyelinase will restore the apoptotic pathway and allow cells to die. Unlike other potential and current therapies for auto-immune disorders this does not rely on a non-specific suppression of the immune system which can prove dangerous for the patient. Instead it is highly selective only for the cells that the body has already targeted for apoptosis after induction of Fas. Consequently the inhibitor has no effect on non-activated T-cells or other cells of the immune system such as the antibody producing B-cells. The inhibitor has shown very clear anti neoplastic properties in mouse xenografts where it sensitises tumours to the effects of cisplatin and Tumour Necrosis Factor and when administered orally, has been shown to remove T-cell lymphomas in mice.

 CRV has to date underwritten the patent costs and ensured a good intellectual property position in the field over the last two years. Now that the inventor has secured finance for the clinical development, CRV were very happy to hand back rights to this promising candidate. This continues the recent trend CRV has shown to help foster new start-up companies, mainly in the cancer field, with Qugen, Singapore and Chroma, Oxford, UK being the most recent. CRV said that it has plans to incorporate another UK based company in the next two months based on cancer pro-drugs and is currently involved in helping seed companies in the Netherlands and Italy.